China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE: 300294)

China Resources Boya Bio-pharmaceutical Group Co.,Ltd Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1,988	1,961	1,532	1,584	753.89	568.75
Trading Asset Securities	3,251	3,362	3,194	2,700	-	-
Cash & Short-Term Investments	5,239	5,324	4,726	4,284	753.89	568.75
Cash Growth	2.53%	12.66%	10.31%	468.21%	32.55%	-52.34%
Accounts Receivable	355.28	275.92	567.02	588.08	681.01	970.14
Other Receivables	352.99	264.4	100.62	67.9	53.21	39.31
Receivables	708.27	540.32	667.64	655.98	734.22	1,009
Inventory	627.58	556.94	666.96	676.84	689.46	621.4
Other Current Assets	13.57	6.43	13.25	29.4	750.08	853.38
Total Current Assets	6,588	6,428	6,073	5,646	2,928	3,053
Property, Plant & Equipment	794.96	676.62	722.81	771.33	809.52	814.8
Long-Term Investments	93.96	100.39	117.09	144.96	311.66	133.34
Goodwill	72.61	72.61	663.84	663.84	663.84	663.84
Other Intangible Assets	263.14	269.31	312.17	169.47	198.6	175.61
Long-Term Deferred Tax Assets	44.96	47.34	44.99	27.44	20.57	26
Long-Term Deferred Charges	107.07	88.15	82.64	161.62	166.41	161.01
Other Long-Term Assets	192.88	146.83	16.24	37.2	60.27	229.1
Total Assets	8,158	7,829	8,033	7,622	5,159	5,257
Accounts Payable	219.87	126.35	303.46	277.53	285.88	250.67
Accrued Expenses	89.75	274.14	290.9	261.19	83.94	273.58
Short-Term Debt	-	-	-	-	220.2	256.83
Current Portion of Long-Term Debt	2.09	0.03	22.18	0.08	55.2	97.56
Current Portion of Leases	-	0.87	2.81	2.06	-	-
Current Income Taxes Payable	22.19	8.58	27.09	41.45	20.54	30.1
Current Unearned Revenue	4.03	12.21	20.58	12.97	14.51	-
Other Current Liabilities	210.65	34.26	38.33	35.66	191.66	47.77
Total Current Liabilities	548.57	456.45	705.34	630.94	871.93	956.51
Long-Term Debt	-	22.15	-	22.15	55	269
Long-Term Leases	2.53	1.4	10.37	11.3	-	-
Long-Term Unearned Revenue	20.51	23.52	27.09	30.98	32.44	35.77
Long-Term Deferred Tax Liabilities	4.35	4.56	5.56	5.94	6.71	6.83
Total Liabilities	575.96	508.07	748.35	701.3	966.08	1,268
Common Stock	504.25	504.25	504.25	511.63	433.32	433.32
Additional Paid-In Capital	4,063	4,063	4,065	4,258	1,947	1,947
Retained Earnings	3,014	2,753	2,616	2,259	1,928	1,732
Treasury Stock	-	-	-	-199.96	-199.96	-199.96
Total Common Equity	7,581	7,320	7,186	6,829	4,108	3,912
Minority Interest	0.8	1.07	99.19	91.4	84.55	76.85
Shareholders' Equity	7,582	7,321	7,285	6,920	4,192	3,989
Total Liabilities & Equity	8,158	7,829	8,033	7,622	5,159	5,257
Total Debt	4.61	24.45	35.36	35.58	330.39	623.39
Net Cash (Debt)	5,234	5,299	4,690	4,248	423.5	-54.64
Net Cash Growth	2.94%	12.99%	10.41%	903.09%	-	-
Net Cash Per Share	10.38	10.49	9.33	9.74	0.99	-0.13
Filing Date Shares Outstanding	504.25	504.25	504.25	504.25	425.94	425.94
Total Common Shares Outstanding	504.25	504.25	504.25	504.25	425.94	425.94
Working Capital	6,040	5,971	5,368	5,015	2,056	2,096
Book Value Per Share	15.03	14.52	14.25	13.54	9.64	9.18
Tangible Book Value	7,245	6,978	6,210	5,996	3,245	3,072
Tangible Book Value Per Share	14.37	13.84	12.31	11.89	7.62	7.21
Buildings	-	527.95	518.01	536.62	506.23	465.93
Machinery	-	625.83	671.97	665.73	632.37	627.88
Construction In Progress	-	39.94	69.34	40.86	80.9	94.55

Source: S&P Capital IQ. Standard template. Financial Sources.